# A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Source: https://onco.cc/trials/nct05102006/  
OnCo record `nct05102006` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.

## Summary

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05102006 by Nanjing Leads Biolabs Co.,Ltd, with 80 participants enrolled, started 2021-11-30. Conditions recorded: Advanced Malignant Tumors. Interventions recorded: LBL-007 Injection and Toripalimab Injection.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05102006
- Phase: 1/2
- Setting: A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Toripalimab in the Treatment of Advanced Malignancies
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05102006: https://clinicaltrials.gov/study/NCT05102006

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct05102006.json